Astia Portfolio Company Alydia Health Acquired by Merck
KENILWORTH, N.J. & MENLO PARK, Calif.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Alydia Health announced today that they have entered into a definitive agreement pursuant to which, after the intended Merck spinoff of Organon, Organon will acquire Alydia Health. Alydia Health is a commercial-stage medical device company focused on preventing maternal morbidity and mortality caused by postpartum hemorrhage (PPH) or abnormal postpartum uterine bleeding. PPH is one of the most common complications of birth, resulting in pharmacologic treatment in up to 10% of mothers and potentially resulting in emergency intervention such as hysterectomy and blood transfusions, and, in some cases, maternal death.1 The transaction is expected to close after Organon has spun off from Merck as a standalone publicly traded company.
Sharon Vosmek included in UKTN's "The most powerful female VCs in UK tech"
Sharon Vosmek included in UKTN's "The most powerful female VCs in UK tech": https://www.uktech.news/women-in-tech/the-most-powerful-female-vcs-in-uk-tech-20210304
Astia Managing Director Angela Holter and Astia Fund featured in Shifter Norway
Norway-based Astia Managing Director Angela Holter talks about Astia's thesis and our Astia Fund in a recent piece in Shift Norway.
Astia Fund selected to the ImpactAssets 50 2021
Astia is excited to announce that Astia Fund has been selected to the ImpactAssets 50 2021! The #IA50 recognizes a diverse group of impact investment fund managers who demonstrate a commitment to generating positive social, environmental and financial impact.